Hypothesis: Metabolic targeting of 5-aminolevulinate synthase by tryptophan and inhibitors of heme utilisation by tryptophan 2,3-dioxygenase as potential therapies of acute hepatic porphyrias-Reference-Cited by-同舟云学术

Hypothesis: Metabolic targeting of 5-aminolevulinate synthase by tryptophan and inhibitors of heme utilisation by tryptophan 2,3-dioxygenase as potential therapies of acute hepatic porphyrias

Published:2019-10 Issue: Volume:131 Page:109314
ISSN:0306-9877
Container-title:Medical Hypotheses
language:en
Short-container-title:Medical Hypotheses

Author:

Badawy Abdulla A.-B.

Funder

Wellcome Trust

UK Medical Research Council.

Publisher

Elsevier BV

Subject

General Medicine

Reference150 articles.

1. Neurovisceral porphyrias: what a hematologist needs to know;Bonkovsky;Hematol Am Soc Hematol Educ Program,2005

2. Effects by heme, insulin, and serum albumin on heme and protein synthesis in chick embryo liver cells cultured in a chemically defined medium, and a spectrofluorometric assay for porphyrin composition;Granick;J Biol Chem,1975

3. Central role of tryptophan pyrrolase in haem metabolism;Badawy;Biochem Soc Trans,1979

4. Animal liver tryptophan pyrrolases – absence of apoenzyme and of hormonal induction mechanism from species sensitive to tryptophan toxicity;Badawy;Biochem J,1976

5. Heme utilization by rat liver tryptophan pyrrolase as a screening test for exacerbation of hepatic porphyrias by drugs;Badawy;J Pharmacol Methods,1981

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammatory pathophysiological mechanisms implicated in postpartum depression;Frontiers in Pharmacology;2022-11-03

2. A Recap of Heme Metabolism towards Understanding Protoporphyrin IX Selectivity in Cancer Cells;International Journal of Molecular Sciences;2022-07-19

3. A Novel 5-Aminolevulinic Acid-Enabled Surgical Loupe System—A Consecutive Brain Tumor Series of 11 Cases;Operative Neurosurgery;2022-03-22

4. Evaluation of Metabolic Changes in Acute Intermittent Porphyria Patients by Targeted Metabolomics;International Journal of Molecular Sciences;2022-03-16

5. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria;Journal of Internal Medicine;2022-01-23